Place of Origin: | China |
Brand Name: | Pharmlab |
Certification: | ISO 9001, USP,GMP |
Model Number: | 1379686-30-2 |
Minimum Order Quantity: | negotiation |
---|---|
Price: | negotiation |
Packaging Details: | Disguised package ; Foil bag |
Delivery Time: | 3-5 work days |
Payment Terms: | Western Union, MoneyGram, T/T, bitcoin |
Supply Ability: | Mass in stock |
Product: | SR9009 | CAS: | 1379686-30-2 |
---|---|---|---|
Appearance: | White Crystalline Powder | Grade: | Pharmaceutical Grade |
Shipping Methods: | EMS,HKEMS,FEDEX,DHL,TNT,Aramex,ETC | Shipping Policy: | 100% Free Resend Policy |
High Light: | legal anabolic supplements,selective androgen receptor modulators |
Also known as Stenabolic, SR9009 has been developed by Scripps Research Institute under the leadership of professor Thomas Burris.
As mentioned beforehand, SR9009 is a synthetic Rev-Erb ligand, which is taken orally. This is a very unique compound. By stimulating the Rev-Erb protein, SR9009 has the ability to greatly influence a lot of regulatory mechanisms in the human body. For instance, it can affect the circadian rhythms, lipid and glucose metabolism, fat-storing cells, as well as macrophages. Hence, Stenabolic will allow the user to lose fat and drastically increase endurance, both of which are very desirable effects for an athlete.
Name | SR9009 |
Systematic (IUPAC) name | ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate |
CAS number | 1379686-30-2 |
Formula | C20H24ClN3O4S |
Appearance | white powder |
Quality Standard | 98% by HPLC |
Application | New generation supplements for gaining mass and cutting edges |
stock | bulk in stock |
assay | HPLC;HNRM;LC-MS |
SR9009 is an agonist of REV-ERB with IC50 = 670 nM for REV-ERBα and IC50 = 800 nM for REV-ERBβ.
SR9009 dose-dependently increases the REV-ERB-dependent repressor activity assessed in HEK293 cells expressing a chimeric Gal4 DNA Binding Domain (DBD) - REV-ERB ligand binding domain (LBD) α or β and a Gal4-responsive luciferase reporter. SR9009 potently and efficaciously suppresses transcription in a cotransfection assay using full-length REV-ERBα along with a luciferase reporter driven by the Bmal1 promoter (SR9009 IC50=710 nM). SR9009 suppresses the expression of BMAL1 mRNA in HepG2 cells in a REV-ERBα/β-dependent manner.
SR9009 are synthetic REV-ERB agonists with activity. SR9009 also inhibits the activity of the SCN clock, with reversible inhibition of circadian oscillations in SCN explants cultured from the Per2:luc reporter mouse.
1)Uses in Medical Treatment
SR9009 will have an extremely varied use in medicine. For instance, the drastic decrease in triglycerides and plasma glucose will be a huge help in the treatment of type 2 diabetes. What's more, Stenabolic will be a crucial element in the treatment of sarcopenia - muscle and strength loss caused by aging.SR9009 will allow doctors to treat obesity in those who for medical reasons cannot train or carry out any exercises, as it can replace exercise.
2)Uses in bodybuilding
SR9009 offers athlete amazing endurance and strength, fat loss, muscle hypertrophy (growth), improved cholesterol and blood sugar levels, and an increased metabolism. Hence, one can expect results similar tothose seen with Cardarine (GW-501516), but with considerably more extra benefits.
Besides, since stenabolic works great both solo or stacked, it will be a very good addition to any steroid or SARMS cycle, and it will give especially impressive results when used together with Cardarine.
Dosages of 20-100mg a day have been reported by users without any negative side effects. From the information we have received, results from SR9009 treatment appear to be dose dependent up to a maximum dosage of 100mg per day. After this dosage, results tend to taper off.
SR9009
Name |
CAS NO. |
Usage |
MK2866 |
841205-47-8 |
medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
MK-677 |
15972-10-0 |
for the treatment of frailty in the elderly |
LGD-4033 |
1165910-22-4 |
pharmacological profile similar to that of enobosarm, |
GW1516 |
317318-70-0 |
For obesity, diabetes, dyslipidemia and cardiovascular disease |
Andarine(S4) |
401900-40-0 |
partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
SR9009 |
1379686-30-2 |
under development at The Scripps Research Institute (TSRI), |
RAD140 |
1182367-47-0 |
New generation for gaining mass and cutting edges |
YK11 |
431579-34-9 |
YK11: a SARM and myostatin inhibitor in one |
Contact Person: Coco
Tel: +8618186204104